# Breast Cancer Program

> **NIH NIH P30** · BAYLOR COLLEGE OF MEDICINE · 2021 · $40,088

## Abstract

BREAST CANCER PROGRAM (BCP)
PROJECT SUMMARY
The main goals of the Breast Program (BCP) are to advance the understanding of breast cancer development,
and the prevention and treatment of breast cancer; to translate laboratory discoveries to clinical practice; to
facilitate intra-programmatic and inter-programmatic interactions; and to provide an enriched learning
environment for students and postdoctoral medical and laboratory-based trainees. The Program has 27
members (22 Research members and 5 Clinical members) and shares 2 members with the Cell Signaling and
Metabolism Program and one member with Cancer Cell and Gene Therapy Program. Jeffrey Rosen, PhD is the
Leader of BCP, and Mothaffar Rimawi, MD, the Co-Leader. BCP includes both a strong basic science group and
a clinical breast center that has a large and active clinical and translational program. As of July 2019, the Program
has total direct funding of $17.4 million, of which $14.2 million is peer reviewed including $6.3 million from the
NCI. In the last 5 years, members of the Program published 301 cancer-related manuscripts in peer-reviewed
journals of which 36% represented intra-programmatic, 21% inter-programmatic, and 65% inter-institutional
collaborations. The BCP is organized around 4 Research Themes: (1) Stem Cells, (2) Treatment Resistance,
(3) Cross Talk and Signaling, and (4) Metastasis and the Tumor Microenvironment. Translation to the clinic is
an integral component of all of these Themes. Our clinical trial portfolio is robust and highly translational. Our
investigators designed and led national and international trials that have the potential to alter the way we
understand and treat breast cancer. BCP investigators translated and led several laboratory discoveries into
national and international clinical trials including 2 trials at the cooperative group level, 2 trials with the TBCRC,
and one global trial. The impact of those trials is likely to alter the way we treat breast cancer. Major
accomplishments of the BCP are: (1) The development of proteogenomics as both a discovery and diagnostic
tool that may identify new therapeutic targets and hypotheses in treatment-resistant advanced breast cancer, (2)
The development of novel small molecule therapeutics to target the unfolded protein response in combination
with chemotherapy in breast cancer, and (3) New insights into the role of RNA splicing in breast cancer
progression. Other achievements include: studies to confirm mechanisms of resistance to endocrine and HER2
targeted therapies, the construction of a unique multiparameter molecular classifier to identify patients whose
tumors can be safely treated with target therapy alone, the identification of novel targetable vulnerabilities in
triple-negative breast cancer (TNBC), the elucidation of signaling cascades involved in bone micrometastasis,
and the definition of 2 “myeloid subtypes” that contribute to the therapeutic response to immune checkpoint
blockade in TNBC. Sever...

## Key facts

- **NIH application ID:** 10239130
- **Project number:** 5P30CA125123-15
- **Recipient organization:** BAYLOR COLLEGE OF MEDICINE
- **Principal Investigator:** Jeffrey Mark Rosen
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $40,088
- **Award type:** 5
- **Project period:** 2007-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10239130

## Citation

> US National Institutes of Health, RePORTER application 10239130, Breast Cancer Program (5P30CA125123-15). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10239130. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*